SWOG clinical trial number
SWOG-8609

VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
90%
Published
Abbreviated Title
VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer
Activated
09/15/1988
Closed
11/15/1990

Research committees

Lung Cancer

Publication Information Expand/Collapse

1997

Teniposide (VM-26) as a single drug treatment for patientss with extensive small cell lung carcinoma. A Phase II study of the Southwest Oncology Group.

PN Grozea;JJ Crowley;VA Canfield;L Kingsbury;SW Ross;GS Beltran;LR Laufman;GR Weiss;RB Livingston Cancer 80(6):1029-1033

1994

SWOG 8609 - a phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC)

V Canfield;P Grozea;J Crowley;R Livingston Lung Cancer 11(Suppl.1):102(#389)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase